Additionally, PI3K/Akt/mammalian target of rapamycin (mTOR) signaling is a well-known oncogenic signaling pathway in both BCR-ABL-dependent and BCR-ABL-independent CML. This evidence concerns the gene PIK3CD and chronic myelogenous leukemia, BCR-ABL1 positive.